BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Coronavirus
      • Glenmark Launches FabiFlu For...
      Coronavirus

      Glenmark Launches FabiFlu For COVID-19 Treatment: All You Need To Know

      The company claimed that the branded tablet for anti-viral favipravir reduced viral load of COVID-19.

      By - Shachi Sutaria |
      Published -  20 Jun 2020 8:55 PM IST
    • Boomlive
      Glenmark Launches FabiFlu For COVID-19 Treatment: All You Need To Know

      Glenmark Pharmaceuticals has launched FabiFlu, a brand of Favipiravir, an antiviral drug to treat COVID-19 after receiving approval from the Drugs Controller General of India (DCGI) on Saturday, June 20. This is the first drug to be orally administered for treating COVID-19 in India.

      The drug is claimed to reduce the viral load of people with mild and moderate symptoms in four days. FabiFlu was launched on the day India reported over 14,000 cases, the highest one-day rise it has witnessed since the first cases in January, 2020.

      The company received approval for manufacturing and marketing of the drug. Glenmark had received permissions to begin clinical trials for the drug on April 30, 2020.

      Glenmark's Role In Favipiravir Production

      Glenmark in a press release stated that the drug can be used for people across all age groups above 20 years of age and can also be orally administered to patients living with other co-morbidities such as diabetes and hypertension.

      The drug reduces the viral load of SARS-CoV-2 within 4 days and provides faster symptomatic improvement. The company has further emphasised that the drug has shown clinical improvement in 88% of COVID-19 cases with mild and moderate symptoms.

      The company is pricing the drug at Rs 103 /tablet which will only be sold when prescribed by a doctor, with its recommended dose being 1800 mg twice on day 1, followed by 800 mg twice daily up to day 14.

      According to the CEO Glen Saldanha, "Glenmark will work closely with the government and medical community to make FabiFlu® quickly accessible to patients across the country."

      The company began its Phase 3 clinical trials on May 12, 2020 with nine hospitals and 150 patients on a randomized basis. The treatment is to be administered for a maximum of 14 days and the results of which were expected in July.

      The pharmaceutical developed its own Active Pharmaceutical Ingredient (API) and its formulation through its in-house Research and Development Team in India. The drug controller body then permitted the company to begin its clinical trials on April 30, 2020.

      Glenmark is currently conducting a Phase 3 trial of a combination of Favipiravir with Umifenovir. The other drug acts as a viral entry inhibitor. This trial is called the Favipiravir and Umifenovir Trial in Indian Hospital Setting (FAITH) Trial.

      What Is Favipiravir?

      Favipiravir, an antiviral drug is sold under the brand name Avigan in Japan. It has earlier been used against Ebola. The antiviral stops the virus from replicating in the body, and in turn reducing the amount of the virus making it non-infectious.

      The drug has been approved in Italy, Japan, China, and Russia for treating COVID-19.

      In two clinical trials conducted in Wuhan and Shenzhen, this drug was seen to act against SARS-CoV-2 while in February, director of China's National Centre for Biotechnological Development recommended the use of this anti-viral.

      The Japanese study, however, started to use Favipiravir on compassionate grounds and only provided it to hospitals that participated in the observational study after seeking an informed consent by the patients.

      Currently, the World Health Organization (WHO) is conducting the Solidarity Trial for checking the efficiency of anti-HIV drugs lopinavir and ritonavir, remdesivir, and plasma therapy against COVID-19. The WHO stopped the hydroxychloroquine (HCQ) trial after a study by Oxford University showed that HCQ had no effect on SARS-CoV-2.

      This Oxford study called the RECOVERY Trial also found that a low-costing c orticosteroid, Dexamethasone was found to reduce COVID-19 deaths by one/third and one/fifth in ventilated and oxygenated patients respectively.

      Also Read: Dexamethasone- Steroid For Treating COVID-19: All You Need To Know

      India has been actively following the plasma therapy at selected hospitals while also using a combination of drugs to treat COVID-19 patients.

      Also Read: Plasma Therapy For COVID-19: All You Need To Know


      Tags

      glenmarkCOVID-19favipiravirfabifluWHOCoronavirus Pandemicfabiflu tablet pricefabiflue
      Read Full Article
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!